An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
Public ClinicalTrials.gov record NCT02962648. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multicentre, Extension Trial to Assess the Safety of Re-dosing of Intravenous Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
Study identification
- NCT ID
- NCT02962648
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pharmacosmos A/S
- Industry
- Enrollment
- 103 participants
Conditions and interventions
Conditions
Interventions
- Iron isomaltoside/ferric derisomaltose Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 8, 2017
- Primary completion
- Jun 11, 2018
- Completion
- Jun 11, 2018
- Last update posted
- Mar 9, 2020
2017 – 2018
United States locations
- U.S. sites
- 22
- U.S. states
- 7
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pharmacosmos Investigational Site | Chula Vista | California | 91910 | — |
| Pharmacosmos Investigational Site 1 | La Mesa | California | 91942 | — |
| Pharmacosmos Investigational Site 2 | La Mesa | California | 91942 | — |
| Pharmacosmos Investigational Site | Northridge | California | 91324 | — |
| Pharmacosmos Investigational Site | Porterville | California | 93257 | — |
| Pharmacosmos Investigational Site | Doral | Florida | 33172 | — |
| Pharmacosmos Investigational Site | Hialeah | Florida | 33012 | — |
| Pharmacosmos Investigational Site | Miami | Florida | 33135 | — |
| Pharmacosmos Investigational Site | Miami | Florida | 33147 | — |
| Pharmacosmos Investigational Site | Miami | Florida | 33165 | — |
| Pharmacosmos Investigational Site | Miami Lakes | Florida | 33014 | — |
| Pharmacosmos Investigational Site | West Palm Beach | Florida | 33409 | — |
| Pharmacosmos Investigational Site | Baton Rouge | Louisiana | 70808 | — |
| Pharmacosmos Investigational Site | Metairie | Louisiana | 70006 | — |
| Pharmacosmos Investigational Site | New Orleans | Louisiana | 70125 | — |
| Pharmacosmos Investigational Site | Shreveport | Louisiana | 71101 | — |
| Pharmacosmos Investigational Site | Plainsboro | New Jersey | 08536 | — |
| Pharmacosmos Investigational Site | Albuquerque | New Mexico | 87109 | — |
| Pharmacosmos Investigational Site | Chattanooga | Tennessee | 37404 | — |
| Pharmacosmos Investigational Site | Houston | Texas | 77030 | — |
| Pharmacosmos Investigational Site 1 | San Antonio | Texas | 78215 | — |
| Pharmacosmos Investigational Site 2 | San Antonio | Texas | 78215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02962648, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 9, 2020 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02962648 live on ClinicalTrials.gov.